Actively Recruiting

Age: 18Years +
All Genders
NCT06823401

Study Investigating Anti-drug Antibodies in NSCLC Patients Exposed to Checkpoint Inhibitors (IMB)

Led by Fondazione Ricerca Traslazionale · Updated on 2026-02-06

270

Participants Needed

2

Research Sites

449 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Non-small cell lung cancer (NSCLC) is one of the leading causes of death in Western countries. Today, a new frontier in the fight against cancer is immunotherapy, a treatment that aims to "awaken" the patient's immune system to help it recognize and attack cancer cells. Among the various approaches, there is significant focus on therapies that activate T lymphocytes, a type of immune cell, encouraging them to react against the tumor. These treatments have led to important progress and represent a hope for the future.

CONDITIONS

Official Title

Study Investigating Anti-drug Antibodies in NSCLC Patients Exposed to Checkpoint Inhibitors (IMB)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically or cytologically confirmed diagnosis of NSCLC
  • Ability to provide blood samples
  • Candidate for treatment with any checkpoint inhibitor (single agent pembrolizumab, atezolizumab, nivolumab, durvalumab, or nivolumab with ipilimumab) in any therapy line
  • Performance status 0-2 (ECOG)
  • Compliance with trial procedures
  • Age 18 years or older
  • Signed informed consent
Not Eligible

You will not qualify if you...

  • Unable to provide blood samples
  • Previous treatment with any checkpoint inhibitor
  • Candidate for checkpoint inhibitor therapy combined with chemotherapy or non-checkpoint inhibitors
  • Pregnancy or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Istituto Tumori Regina Elena

Roma, RM, Italy, 000144

Enrolling by Invitation

2

Istituto Tumori Regina Elena

Roma, RM, Italy, 00128

Actively Recruiting

Loading map...

Research Team

F

Federico FC Cappuzzo, PI

CONTACT

G

Grisel GM Maver Militello, Monitor

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study Investigating Anti-drug Antibodies in NSCLC Patients Exposed to Checkpoint Inhibitors (IMB) | DecenTrialz